Latest MediSapiens Ltd. Stories
HELSINKI, November 5, 2012 /PRNewswire/ -- MediSapiens Ltd, a Finnish company developing web-based data applications for the pharmaceutical industry, today announced that Bayer HealthCare Pharmaceuticals has purchased a new software solution developed by MediSapiens. The software, called OncoGenomics Explorer [http://www.medisapiens.com ] will provide Bayer HealthCare Pharmaceuticals with a centralized access to unified global genomics data for utilization across the entire...
HELSINKI, Finland and SAN FRANCISCO, September 17, 2012 /PRNewswire/ -- MediSapiens launches first-in-kind fully integrated and unified cloud computing application that harnesses the power of Big Data and enables knowledge-based drug discovery and repositioning for personalized genomics. This application, called OncoGenomics Explorer, is the next stage of bioinformatics applications for drug discovery. Unlike other cloud computing genomics applications, the Oncogenomics...
HELSINKI, October 11, 2011 /PRNewswire/ -- MediSapiens Ltd and Bayer HealthCare Pharmaceuticals have agreed to develop a platform for genomics data management and analysis in Oncology. The platform will enable Bayer to more effectively utilize genomics data in Oncology research, such utilization to be conducted in compliance with respective patients' informed consent and applicable laws and regulations. "Genomics data is increasingly used both in pre-clinical and...
HELSINKI, Finland, September 29, 2011 /PRNewswire/ -- MediSapiens Ltd [http://www.medisapiens.com ], a Finnish bioinformatics company, has released the most comprehensive map of human gene expression yet for public use. The data is available through a graphical tool, Transcriptome Viewer [http://www.medisapiens.com/transcriptome-viewer-overview ], at the home page of MediSapiens Ltd [http://www.medisapiens.com ], allowing exploration of the expression activity of genes across...
HELSINKI, June 1, 2010 /PRNewswire/ -- MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures. MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world's largest unified gene expression...
